All In Biotech

NDA 218145 · Otsuka

Simtriyo

Centanafadine Hydrochloride · Oral

NovelPriority review

CDER novel approval, Jul 24, 2026: To treat attention-deficit hyperactivity disorder

Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Jul 24, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

25

12 Phase 3, 5 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL IDEATION AND BEHAVIORS IN PEDIATRIC PATIENTS AGED 6 YEARS AND OLDER; and ABUSE, MISUSE AND ADDICTION Suicidal Ideation and Behaviors in Pediatric Patients 6 Years of Age and Older In a short-term (6-week) clinical study, higher rates of suicidal ideation and behavior were reported in SIMTRIYO-treated pediatric patients with attention deficit/hyperactivity disorder (ADHD) aged 6 to 12 years than in pediatric patients treated with placebo. All pediatric patients 6 years of age or older treated with SIMTRIYO should be monitored closely for suicidal ideation and behaviors, clinical worsening, or unusual changes in behavior, especially during the initial months of therapy. Families and caregivers should be advised of the need for close observation and communication with the healthcare provider. Consider stopping SIMTRIYO in patients who experience emergent suicidal ideation...

What it is approved for

From the label in effect Jul 31, 2026.

SIMTRIYO is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and pediatric patients 6 years of age and older weighing at least 20 kg. Limitations of Use The use of SIMTRIYO is not recommended in pediatric patients: Younger than 6 years of age because this pediatric subpopulation had a higher incidence of weight loss than pediatric patients 6 years of age and older [see Use in Specific Populations (8.4) ] . Weighing less than 20 kg because of a lack of data for this subpopulation and the risk of weight loss [see Use in Specific Populations (8.4) ] . SIMTRIYO is a norepinephrine-dopamine-serotonin reuptake inhibitor and central nervous system stimulant indicated for the treatment of ADHD in adults and pediatric patients 6 years of age and older weighing at least 20 kg. ( 1 ) Limitations of Use The use of SIMTRIYO is not recommended in pediatric patients: Younger than 6 years of age because this pediatric subpopulation had a higher incidence of weight loss than pediatric patients 6 years of age and older. ( 8.4 ) Weighing less than 20 kg because of a lack of data for this subpopulation and the risk of weight loss. ( 8.4 ).

Mechanism: Centanafadine has inhibitory activity at norepinephrine (NE), dopamine (DA), and serotonin (5-HT) reuptake transporters and is a central nervous system stimulant. The mechanism of action of centanafadine in the treatment of ADHD is unclear; however, its efficacy could be mediated through its activity as a norepinephrine-dopamine-serotonin reuptake inhibitor.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 24, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
3 products under this application
  • SIMTRIYO · CENTANAFADINE HYDROCHLORIDE EQ 140MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • SIMTRIYO · CENTANAFADINE HYDROCHLORIDE EQ 210MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • SIMTRIYO · CENTANAFADINE HYDROCHLORIDE EQ 280MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Centanafadine" as an intervention, any sponsor and status, largest first.

All 25 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 14 on PubMed

Sponsor: Otsuka

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.